Loading…
Loading…
PXCLF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PXCLF and 80,000+ other tickers.
See exactly how PXCLF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PXCLF and 80,000+ other tickers.
Phoenix Copper Limited, alongside its affiliated entities, specializes in mineral exploration and mining, primarily across North America. The company's focus includes a range of precious and base metals, specifically seeking deposits of copper, zinc, gold, lead, tungsten, cobalt, and silver. Its most significant undertaking is the Empire Mine property, an asset in which it holds an 80% interest, situated in Mackay, Idaho, USA. The company, established in 2013 and headquartered in Road Town, British Virgin Islands, was formerly known as Phoenix Global Mining Limited before officially rebranding as Phoenix Copper Limited in July 2019.
Phoenix Copper Ltd (AIM:PXC, OTCQX:PXCLF, FRA:5HR) said it plans to raise around £2.3 million through a placing and subscription at a steep discount, while warning that further funding will still be needed before the end of September. The AIM-listed Idaho copper developer is proposing to issue around 460 million new shares at 0.5p each, a 54.5% discount to the 1.1p closing mid-market price on 2 July.
Phoenix Copper Ltd (AIM:PXC, OTCQX:PXCLF, FRA:5HR) said it plans to raise around £2.3 million through a placing and subscription at a steep discount, while...
Leadership suspensions and a boardroom departure triggered sharp sell-offs at two market minnows this week, with interim management of both businesses left...
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the...
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds...